NAII · Natural Alternatives International Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $35.10M | $32.30M | $33.33M | $32.41M | $26.94M | $30.89M | $24.82M | $23.21M | $30.83M | - |
| Gross Profit | $383.0K | $2.49M | $4.40M | $1.67M | $1.83M | $2.26M | $387.0K | $1.92M | $3.14M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $4.40M | $4.34M | $4.11M | $4.45M | $3.93M | $4.09M | $3.90M | $3.87M | $3.68M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $1.14M | $1.13M | $1.17M | $1.20M | $1.10M | $1.13M | $1.20M | $1.10M | $1.15M | - |
| Operating Income | ($4.01M) | ($1.85M) | $284.0K | ($2.78M) | ($2.10M) | ($1.84M) | ($3.51M) | ($1.95M) | ($544.0K) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $68.0K | $224.0K | $92.0K | ($675.0K) | ($456.0K) | ($431.0K) | ($761.0K) | ($390.0K) | ($189.0K) | - |
| Net Income | ($4.31M) | ($2.55M) | ($291.0K) | ($2.19M) | ($2.19M) | ($1.98M) | ($3.07M) | ($1.58M) | ($695.0K) | - |
| EPS - Basic | ($0.72) | ($0.42) | ($0.05) | ($0.37) | ($0.37) | ($0.33) | ($0.52) | ($0.27) | ($0.12) | - |
| EPS - Diluted | ($0.72) | ($0.42) | ($0.05) | ($0.37) | ($0.37) | ($0.33) | ($0.52) | ($0.27) | ($0.12) | - |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.20M | $3.75M | $7.74M | $12.32M | $10.61M | $10.16M | $11.98M | $12.41M | $16.75M | $13.60M |
| Accounts Receivable | $20.59M | $17.76M | $18.91M | $14.64M | $11.65M | $17.62M | $16.89M | $11.22M | $9.75M | $7.02M |
| Inventory | $29.93M | $33.43M | $30.65M | $24.87M | $26.99M | $25.93M | $24.25M | $21.07M | $23.30M | $29.69M |
| Accounts Payable | $18.16M | $16.55M | $20.09M | $15.35M | $12.82M | $9.95M | $12.74M | $6.97M | $7.61M | $7.78M |
| Current Assets | $63.99M | $61.52M | $65.05M | $59.28M | $58.52M | $62.48M | $61.61M | $54.36M | $57.75M | $57.01M |
| Total Assets | $154.88M | $153.30M | $156.94M | $151.94M | $154.94M | $161.27M | $162.34M | $153.21M | $160.25M | $134.15M |
| Current Liabilities | $39.13M | $32.85M | $33.90M | $28.80M | $23.31M | $24.43M | $23.46M | $13.65M | $15.44M | $15.88M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $91.77M | $86.25M | $87.92M | $83.51M | $78.33M | $81.08M | $79.75M | $69.11M | $71.44M | $45.38M |
| Stockholders' Equity | $63.11M | $67.05M | $69.02M | $68.43M | $76.62M | $80.19M | $82.59M | $84.10M | $88.81M | $88.77M |
| Retained Earnings | $52.24M | $56.55M | $59.10M | $59.39M | $66.61M | $70.98M | $72.97M | $74.84M | $79.49M | $80.18M |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($4.02M) | - | - | ($3.44M) | - | - | $4.50M | - |
| Investing Cash Flow | - | - | ($1.03M) | - | - | ($301.0K) | - | - | ($1.28M) | - |
| Financing Cash Flow | - | - | $472.0K | - | - | $1.92M | - | - | ($73.0K) | - |
| CapEx | - | - | $1.03M | - | - | $301.0K | - | - | $1.28M | - |
| Free Cash Flow | - | - | ($5.05M) | - | - | ($3.74M) | - | - | $3.22M | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 17.36 | - | - | 1.89 | - | - | -4.63 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.8% | -1.7% | -0.2% | -1.4% | -1.4% | -1.2% | -1.9% | -1.0% | -0.4% | - |
| Return on equity | -6.8% | -3.8% | -0.4% | -3.2% | -2.9% | -2.5% | -3.7% | -1.9% | -0.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.64 | 1.87 | 1.92 | 2.06 | 2.51 | 2.56 | 2.63 | 3.98 | 3.74 | 3.59 |
| Quick ratio | 0.87 | 0.85 | 1.01 | 1.19 | 1.35 | 1.50 | 1.59 | 2.44 | 2.23 | 1.72 |
| Cash ratio | 0.24 | 0.11 | 0.23 | 0.43 | 0.46 | 0.42 | 0.51 | 0.91 | 1.08 | 0.86 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.45 | 2.29 | 2.27 | 2.22 | 2.02 | 2.01 | 1.97 | 1.82 | 1.80 | 1.51 |
| Liabilities / Assets | 0.59 | 0.56 | 0.56 | 0.55 | 0.51 | 0.50 | 0.49 | 0.45 | 0.45 | 0.34 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 1.17 | 0.97 | 1.09 | 1.30 | 1.00 | 1.19 | 1.02 | 1.10 | 1.32 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 311d | 378d | 336d | 280d | 366d | 306d | 357d | 331d | 276d | - |
| Days payable outstanding | 189d | 187d | 220d | 173d | 174d | 118d | 187d | 110d | 90d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.3x | 0.3x | 0.2x | 0.3x | 0.3x | 0.4x | 0.4x | 0.4x | 0.4x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | 6.5x | - | - | - | - | - | 35.1x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -79.0% | 49.3% | 94.6% | 331.3% | -5.0% | -28.0% | - | - | - | - |
| Operating income growth (YoY) | -91.1% | 33.6% | - | 20.9% | -7.6% | -237.5% | - | - | - | - |
| Net income growth (YoY) | -97.2% | -16.5% | 85.3% | 28.6% | -38.5% | -185.2% | - | - | - | - |
| EPS growth (YoY) | -94.6% | -13.5% | 84.8% | 28.8% | -37.0% | -175.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -35.0% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | -4.0% | - |
| Book value growth (YoY) | -17.6% | -2.0% | -13.9% | -17.2% | -8.9% | -9.7% | -7.0% | - | - | -0.8% |
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing NATURAL ALTERNATIVES INTERNATIONAL INC against the 5 most active filers in the same SIC group.